BioPharmSignal logoBioPharmSignal

Biotech News

Neurocrine Biosciences to Present at Upcoming Investor Conferences in September

Neurocrine Biosciences (NBIX)Neurocrine BiosciencesConference / presentation

SAN DIEGO, Sept. 2, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that its executives will participate at the following investor conferences: Wells Fargo 21 st Annual Healthcare Conference. Fireside chat on Wednesday, September 9, 2026 at 12:45 PM ET in Boston

Related news

KTTAPasithea Therapeutics2026-09-03 20:05 EST

Pasithea Therapeutics Announces Participation in Two September 2026 Investor Conferences

NBIXNeurocrine Biosciences2026-08-12 12:30 EST

Neurocrine Biosciences Announces Publication of KINECT-PRO™ Findings Demonstrating INGREZZA® (valbenazine) Capsules Improved Patient-Reported Quality of Life and Daily Functioning for People Living with Tardive Dyskinesia

NBIXNeurocrine Biosciences2026-08-07 12:30 EST

Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating NBIP-'1968, a GLP-1/GIP/Glucagon Receptor Triple Agonist

HRMYHarmony Biosciences2026-09-03 12:05 EST

Harmony Biosciences Announces Poster Presentations at the 16th European Epilepsy Congress

HRMYHarmony Biosciences2026-08-27 12:05 EST

Harmony Biosciences to Participate in 2026 Cantor Global Healthcare Conference

XENEXenon2026-09-03 20:01 EST

Xenon to Present at Wells Fargo Healthcare Conference

CLNNClene Inc.2026-08-17 12:30 EST

Clene to Present at the Emerging Growth Conference

GANXGain Therapeutics2026-09-17 11:00 EST

Gain Therapeutics to Participate at ROTH Fifth Annual Healthcare Opportunities Conference

TNXPTonix Pharmaceuticals2026-09-02 11:00 EST

Tonix Pharmaceuticals to Participate in Cantor’s 2026 Global Healthcare Conference

CLNNClene Inc.2026-07-29 12:30 EST

Clene to Present at The Canaccord 46th Annual Growth Conference

View all latest news

Neurocrine Biosciences

Neuroscience and Endocrinology Portfolio Neurocrine Biosciences discovers, develops and commercializes medicines for neuropsychiatric, neurological, endocrine and immunological disorders. Its business combines several first-in-class commercial products with a deep mid- and late-stage pipeline. Commercial Medicines The portfolio includes...

Recent company news

NBIXNeurocrine Biosciences2026-09-02 20:01 EST

Neurocrine Biosciences to Present at Upcoming Investor Conferences in September

NBIXNeurocrine Biosciences2026-08-12 12:30 EST

Neurocrine Biosciences Announces Publication of KINECT-PRO™ Findings Demonstrating INGREZZA® (valbenazine) Capsules Improved Patient-Reported Quality of Life and Daily Functioning for People Living with Tardive Dyskinesia

NBIXNeurocrine Biosciences2026-08-07 12:30 EST

Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating NBIP-'1968, a GLP-1/GIP/Glucagon Receptor Triple Agonist

NBIXNeurocrine Biosciences2026-07-30 20:01 EST

Neurocrine Biosciences Reports Second-Quarter 2026 Financial Results

NBIXNeurocrine Biosciences2026-07-23 20:05 EST

Neurocrine Biosciences Announces Key Leadership Hiring, Promotions

Stock data

Close
151.83 USD
Market cap
15.57B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States